7-days of FREE Audio papers, translation & more with Prime
7-days of FREE Prime access
7-days of FREE Audio papers, translation & more with Prime
7-days of FREE Prime access
https://doi.org/10.30574/ijsra.2023.10.2.1021
Copy DOIPublication Date: Dec 30, 2023 | |
License type: cc-by |
The aim of the present work is to develop extended-release capsules of Galantamine HBr (8mg) and compare them with the reference listed drug (Reminyl or Razadyne). The capsules were prepared using Pelletization technique and evaluated for preformulation characteristics, physical, and chemical parameters. The In-vitro dissolution studies were conducted using USP type II (paddle apparatus) in 900 ml of pH 6.5 phosphate buffer. Among all the formulations, F7 was found to be pharmaceutically equivalent to reference listed drug due to its similarity factor (f2= 96) in drug release profile. The F7 formulation was loaded for stability study and no change was observed, which indicates that the optimized F7 formulation was stable.
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.